CRISPR THERAPEUTICS AG
(NASDAQ: CRSP)

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

47.930

-1.010 (-2.06%)
Range 47.600 - 49.872   (4.77%)
Open 48.510
Previous Close 48.940
Bid Price 67.000
Bid Volume 8
Ask Price 67.410
Ask Volume 10
Volume 1,159,402
Value -
Remark
Delayed prices. Updated at 31 Oct 2024 04:00.
Data powered by
View All Events


Loading Chart...

Please login to view stock data and analysis